{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["furmonertinib"]],"indication":"resected EGFR-mutant stage IB-IIA non-small cell lung carcinoma","name":"ATHEM","nct_id":"NCT05165355","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=athem-nct05165355. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ATHEM","arms":[{"description":"Furmonertinib (80 mg orally, once daily) for 3 years.","label":"Experimental group","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-02","type":"ESTIMATED"},"conditions":["NSCLC","EGF-R Positive Non-Small Cell Lung Cancer"],"enrollment":{"count":90,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Furmonertinib","otherNames":[],"type":"DRUG"}],"last_update":"2022-01-18","lead_sponsor":"Tongji University","official_title":"A Phase II, Single-armed Study to Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection.","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2024-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease Free Survival (DFS) rate at 2 years","timeFrame":"From date of receiving therapy until date of disease recurrence or death (by any cause in the absence of recurrence), up to approximately 4 years. Assessed at 2 years."}],"references":[],"start_date":{"date":"2021-12-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma","url":"https://clinicaltrials.gov/study/NCT05165355"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/athem-nct05165355"}